| Autor: |
Shari R, Lipner, Warren S, Joseph, Tracey C, Vlahovic, Richard K, Scher, Phoebe, Rich, Mahmoud, Ghannoum, C Ralph, Daniel, Boni, Elewski |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of drugs in dermatology : JDD. 20(10) |
| ISSN: |
1545-9616 |
| Popis: |
Onychomycosis affects around 14% of individuals in North America and Europe and is undertreated. Treatment is challenging as toenail growth can take 12ndash;18 months, the nail plate may prevent drug penetration, and disease recurrence is common. National guidelines/consensus documents on onychomycosis diagnosis and treatment were last published more than 5 years ago and updated medical guidance is needed.This document aims to provide recommendations for the diagnosis and pharmaceutical treatment of toenail onychomycosis following a roundtable discussion with a panel of dermatologists, podiatrists, and a microbiologist specializing in nail disease.There was a general consensus on several topics regarding onychomycosis diagnosis, confirmatory laboratory testing, and medications. Onychomycosis should be assessed clinically and confirmed with microscopy, histology, and/or culture. Terbinafine is the primary choice for oral treatment and efinaconazole 10% for topical treatment. Efinaconazole can also be considered for off-label use for maintenance to prevent recurrences. For optimal outcomes, patients should be counseled regarding treatment expectations as well as follow-up care and maintenance post-treatment.This article provides important updates to previous guidelines/consensus documents to assist dermatologists and podiatrists in the diagnosis and treatment of toenail onychomycosis. J Drugs Dermatol. 2021;20(10):1076-1084. doi:10.36849/JDD.6291. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
